Affibody Medical Investor Relations
Categories:
Navigation:
Regulatory
June 13, 2025
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study
Solna, Sweden, June 13, 2025. Affibody’s licensee Rallybio Corporation (Rallybio) has announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, an innovative, once-weekly,...
Read more
